Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression

Neuroendocrinology Letters

Volumn 34, Issue 4, 2013, Pages 287-293

  Sos, Peter ^a   Klirova, Monika ^a   Novak, Tomas ^a   Kohutova, Barbora ^a   Horacek, Jiri ^a   Palenicek, Tomas ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

Author keywords

Antidepressant; Ketamine; Major depressive disorder; NMDA; Nor ketamine; Psychotomimetic

Indexed keywords

KETAMINE; PLACEBO;

ADULT; AGED; ANTIDEPRESSANT ACTIVITY; ARTICLE; BLUNTED AFFECT; CLINICAL ARTICLE; CONFUSION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE DURATION; DISSOCIATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; EUPHORIA; FEMALE; GAS CHROMATOGRAPHY; HOSPITAL PATIENT; HUMAN; HYPERTENSION; LOADING DRUG DOSE; MAJOR DEPRESSION; MALE; MASS SPECTROMETRY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PERCEPTION DISORDER; SIDE EFFECT; THERAPY EFFECT;

EID: 84880555463     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Anis NA, Berry SC, Burton NR, Lodge D (1983). The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspar-tate. Br J Pharmacol 79: 565-575. (Pubitemid 13055426)
2. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000). Antidepressant effects of ketamine in depressed patients. Biological psychiatry 47: 351-354. (Pubitemid 30109248)
3. Bunney BG, Bunney WE (2012). Rapid-acting antidepressant strategies: mechanisms of action. Int J Neuropsychopharmacol 15: 695-713.
4. Dalgarno PJ, Shewan D (1996). Illicit use of ketamine in Scotland. J Psychoactive Drugs 28: 191-199. (Pubitemid 26234535)
5. Diazgranados N, Ibrahim LA, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, et al. (2010a). A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67: 793-802.
6. Diazgranados N, Ibrahim LA, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DA, Machado-Vieira R, Zarate CA, Jr. (2010b). Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 71: 1605-1611.
7. Hetem LA, Danion JM, Diemunsch P, Brandt C (2000). Effect of a subanesthetic dose of ketamine on memory and conscious awareness in healthy volunteers. Psychopharmacology 152: 283-288.
8. Horacek J, Brunovsky M, Novak T, Tislerova B, Palenicek T, Bubenikova-Valesova V, Spaniel F, Koprivova J, et al. (2010). Subanesthetic dose of ketamine decreases prefrontal theta cordance in healthy volunteers: implications for antidepressant effect. Psychol Med 40: 1443-1451.
9. Kornhuber J, Weller M (1997). Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatr 41: 135-144. (Pubitemid 27062653)
10. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB, Jr., et al. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51: 199-214. (Pubitemid 24081509)
11. Montgomery SA, Åsberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatr 134: 382-389. (Pubitemid 9136500)
12. Murrough JW (2012). Ketamine as a novel antidepressant: from synapse to behavior. Clin Pharmacol Ther 91: 303-309.
13. Overall JE, Donald RG (1962). The brief psychiatric rating scale. Psychol Rep 10: 799-812.
14. Passie T, Karst M, Borsutzky M, Wiese B, Emrich HM, Schneider U (2003). Effects of different subanaesthetic doses of (S)-ketamine on psychopathology and binocular depth inversion in man. J Psychopharmacol 17: 51-56. (Pubitemid 36373140)
15. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, et al. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59: 22-33. (Pubitemid 29001829)
16. Skolnick P (1999). Antidepressants for the new millennium. Eur J Pharmacol 375: 31-40.
17. Skolnick P, Popik P, Trullas R (2009). Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 30: 563-569.
18. 123I] CNS-1261 SPET study. Psychopharmacology 197: 401-408.
19. Vollenweider FX, Kometer M (2010). The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 11: 642-651.
20. Zarate Jr C, Singh J, Carlson P, Brutsche N, Ameli R, Luckenbaugh D, Charney D, Manji H (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63: 856-864. (Pubitemid 44188478) Czech Republic